News articles about Titan Pharmaceuticals (OTCMKTS:TTNP) have been trending somewhat positive this week, according to Alpha One Sentiment Analysis. The research group, a division of Accern, ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Alpha One ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Titan Pharmaceuticals earned a media sentiment score of 0.16 on Alpha One’s scale. Alpha One also gave press coverage about the specialty pharmaceutical company an impact score of 0 out of 100, meaning that recent news coverage is extremely unlikely to have an impact on the stock’s share price in the near term.

Separately, Roth Capital set a $10.00 price objective on shares of Titan Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, March 20th.

Shares of Titan Pharmaceuticals (OTCMKTS:TTNP) traded down 6.67% on Friday, reaching $2.80. 125,348 shares of the company’s stock were exchanged. The stock has a market cap of $59.35 million and a price-to-earnings ratio of 13.93. Titan Pharmaceuticals has a one year low of $2.70 and a one year high of $8.74. The company’s 50 day moving average is $3.36 and its 200-day moving average is $4.16.

COPYRIGHT VIOLATION NOTICE: This report was published by Financial Market News and is the sole property of of Financial Market News. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.financial-market-news.com/2017/04/22/titan-pharmaceuticals-ttnp-receives-media-sentiment-score-of-0-16.html.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company’s segment is engaged in the development of pharmaceutical products. The Company’s product development programs utilize its long-term drug delivery platform, ProNeura.

Receive News & Ratings for Titan Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.